| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422771 | 2014-12-19 |
| Publication Number | Publication Date |
|---|---|
| MA41179Atrue MA41179A (en) | 2017-10-24 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041179AMA41179A (en) | 2014-12-19 | 2015-12-16 | PARG INHIBITOR COMPOUNDS |
| Country | Link |
|---|---|
| US (4) | US10508086B2 (en) |
| EP (2) | EP3233845B1 (en) |
| JP (1) | JP6673920B2 (en) |
| KR (1) | KR102682782B1 (en) |
| CN (2) | CN107295799B (en) |
| AU (1) | AU2015365602B2 (en) |
| BR (1) | BR112017012707B1 (en) |
| CA (1) | CA2969298C (en) |
| ES (1) | ES2886471T3 (en) |
| IL (1) | IL252745B (en) |
| MA (1) | MA41179A (en) |
| MX (1) | MX380901B (en) |
| RU (1) | RU2017125520A (en) |
| SG (1) | SG11201704843QA (en) |
| WO (1) | WO2016097749A1 (en) |
| ZA (1) | ZA201704383B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41140A (en) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS PARG INHIBITORS |
| MA41179A (en) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | PARG INHIBITOR COMPOUNDS |
| EP3947351A4 (en)* | 2019-03-29 | 2022-12-07 | Board of Regents, The University of Texas System | SMALL MOLECULAR PARG INHIBITORS AND METHODS OF USE |
| CN114555593A (en)* | 2019-09-20 | 2022-05-27 | 伊迪亚生物科学有限公司 | 4-substituted indole and indazole sulfonamide derivatives as PARG inhibitors |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| US12295960B2 (en) | 2021-10-17 | 2025-05-13 | University of South Alabama Foundation for Research and Commercialization | Cancer treatment |
| EP4479387A1 (en) | 2022-02-14 | 2024-12-25 | ARase Therapeutics Inc. | Inhibitors of parg |
| JP2025509180A (en) | 2022-03-04 | 2025-04-11 | 上海瓔黎薬業有限公司 | Compounds containing five-membered heteroaryl ring structures, pharmaceutical compositions and uses thereof |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| MX2024011545A (en) | 2022-03-23 | 2024-09-26 | Ideaya Biosciences Inc | PIPERAZINE-SUBSTITUTED INDAZOLE COMPOUNDS AS PARG INHIBITORS. |
| CN114685283B (en)* | 2022-04-06 | 2024-02-27 | 南京艾康生物科技有限公司 | Preparation method of 1- (fluoromethyl) cyclopropylamine hydrochloride |
| JP2025515506A (en)* | 2022-04-28 | 2025-05-15 | ダナトラス ファーマシューティカルズ カンパニー、リミテッド | Tricyclic heterocyclic derivatives, compositions thereof and uses thereof |
| WO2023205914A1 (en)* | 2022-04-28 | 2023-11-02 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| KR20250012101A (en) | 2022-05-17 | 2025-01-23 | 858 테라퓨틱스, 인크. | Inhibitor of PARG |
| KR20250028378A (en)* | 2022-06-29 | 2025-02-28 | 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 | Five-membered and six-membered fused nitrogen-containing compounds, intermediates thereof, methods for their preparation and uses |
| KR20250034167A (en)* | 2022-07-19 | 2025-03-10 | 에보포인트 바이오사이언시스 컴퍼니 리미티드 | Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof and use thereof |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| AU2023355735A1 (en) | 2022-10-03 | 2025-04-03 | Forx Therapeutics Ag | Parg inhibitory compound |
| CN120051465A (en)* | 2022-10-13 | 2025-05-27 | 韩美药品株式会社 | Novel heterobicyclic compounds for inhibiting YAP-TEAD interactions and pharmaceutical compositions containing the same |
| WO2024120519A1 (en)* | 2022-12-09 | 2024-06-13 | 捷思英达控股有限公司 | Tead inhibitor, preparation method therefor. and medical use thereof |
| WO2024173234A1 (en)* | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2024222842A1 (en)* | 2023-04-27 | 2024-10-31 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| WO2024243304A2 (en)* | 2023-05-23 | 2024-11-28 | Quantx Biosciences Us, Inc. | Bicyclic heteroaryl compounds |
| CN119143747A (en)* | 2023-06-16 | 2024-12-17 | 上海璎黎药业有限公司 | Heteroaromatic ring structure compound, pharmaceutical composition and application thereof |
| WO2025035108A2 (en)* | 2023-08-10 | 2025-02-13 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025098445A1 (en)* | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg inhibitor, and preparation method and use thereof |
| WO2025108225A1 (en)* | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | Nitrogen-containing tricyclic derivative as parg inhibitor |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1157858A (en) | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Quinazoline derivatives |
| DE4407047A1 (en) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SI0880508T1 (en) | 1996-02-13 | 2003-10-31 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EP1131856A1 (en) | 1998-11-12 | 2001-09-12 | BAE Systems Electronics Ltd. | Scanning of electromagnetic beams |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CZ305827B6 (en) | 1999-02-10 | 2016-03-30 | Astrazeneca Ab | Indole derivatives |
| DE19927415A1 (en) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinyl urea derivatives |
| PE20010306A1 (en)* | 1999-07-02 | 2001-03-29 | Agouron Pharma | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| WO2001092224A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (en) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
| WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| EE200300015A (en) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as inhibitors of angiogenesis |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| SI1719773T1 (en) | 2004-02-24 | 2009-08-31 | Japan Tobacco Inc | Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor |
| US20070049593A1 (en)* | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| CA2560741C (en) | 2004-03-25 | 2013-08-06 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| US20070032496A1 (en)* | 2005-07-26 | 2007-02-08 | Hergenrother Paul J | Compounds for the Treatment of Neurodegeneration and Stroke |
| BRPI0706411A2 (en)* | 2006-01-24 | 2011-03-29 | Lilly Co Eli | compound, pharmaceutical composition, method of preparing an indole or a pharmaceutically acceptable salt thereof, and use of a compound |
| WO2007107469A1 (en) | 2006-03-20 | 2007-09-27 | F. Hoffmann-La Roche Ag | Methods of inhibiting btk and syk protein kinases |
| WO2009047255A1 (en) | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| EP2211854A4 (en) | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors |
| AU2009272034B2 (en)* | 2008-07-17 | 2011-10-13 | Asahi Kasei Pharma Corporation | Nitrogenated bicyclic heterocyclic compound |
| CN101429191B (en) | 2008-11-03 | 2012-05-23 | 中国药科大学 | Use of substituted tetrahydroisoquinoline derivatives |
| EP2523559A4 (en) | 2010-01-13 | 2013-11-06 | Glaxosmithkline Llc | Compounds and methods |
| ES2534804T3 (en)* | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
| US20130053375A1 (en) | 2010-05-07 | 2013-02-28 | Glaxo Group Limited | Amino-quinolines as kinase inhibitors |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| AU2011344270A1 (en) | 2010-12-17 | 2013-07-18 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| EP2471363A1 (en) | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Use of aryl-, heteroaryl- and benzylsulfonamide carboxylic acids, -carboxylic acid esters, -carboxylic acid amides and -carbonitriles and/or its salts for increasing stress tolerance in plants |
| WO2012160464A1 (en) | 2011-05-26 | 2012-11-29 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| US9938236B2 (en) | 2012-12-27 | 2018-04-10 | Drexel University | Antiviral agents against HBV infection |
| CA2939021C (en) | 2014-02-11 | 2022-07-12 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| MX382781B (en) | 2014-04-02 | 2025-03-13 | Intermune Inc | ANTI-FIBROTIC PYRIDINONES. |
| MA41140A (en) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS PARG INHIBITORS |
| MA41179A (en) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | PARG INHIBITOR COMPOUNDS |
| US11104690B2 (en) | 2016-11-18 | 2021-08-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| EP3947351A4 (en) | 2019-03-29 | 2022-12-07 | Board of Regents, The University of Texas System | SMALL MOLECULAR PARG INHIBITORS AND METHODS OF USE |
| CN114555593A (en) | 2019-09-20 | 2022-05-27 | 伊迪亚生物科学有限公司 | 4-substituted indole and indazole sulfonamide derivatives as PARG inhibitors |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| MX2024011545A (en) | 2022-03-23 | 2024-09-26 | Ideaya Biosciences Inc | PIPERAZINE-SUBSTITUTED INDAZOLE COMPOUNDS AS PARG INHIBITORS. |
| Publication | Publication Date | Title |
|---|---|---|
| MA41179A (en) | PARG INHIBITOR COMPOUNDS | |
| MA64121B1 (en) | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS | |
| MX2023005636A (en) | Benzimidazolone derived inhibitors of bcl6. | |
| MA47043B1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| MA38380A1 (en) | Quinazoline inhibitors of activation of mutant forms of epidermal growth receptor (EGFR) | |
| MX383856B (en) | COMPOUNDS AND COMPOSITIONS FOR INHIBITING SHP2 ACTIVITY. | |
| EA201892666A1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydro-pyridazine-4-carboxamides | |
| MA53399B1 (en) | Substituted pyrazoles as inhibitors of human plasma kallikrein | |
| MA38483A1 (en) | Inhibitors of ido | |
| MA43979B1 (en) | 1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders | |
| TN2014000420A1 (en) | INDOLE AND INDAZOLE DERIVATIVES THAT ACTIVATE MPK | |
| MA34969B1 (en) | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | |
| MA40123A1 (en) | Pyrimidines used as factor xia inhibitors | |
| MA39219B1 (en) | New lrrk2 Kinase Inhibitor Compounds Used to Treat Parkinson's, Alzheimer's and Amyotrophic Lateral Sclerosis | |
| MA38391A1 (en) | Pyridinyl and triazolone pyridinyl derivatives of fusion | |
| MA40955B1 (en) | 2-amino-6- (difluoromethyl) -5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MA46229B1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| MA44948A1 (en) | Bace 1 inhibitors | |
| MA37691B1 (en) | 5-amino [1,4] thiazines as bace1 inhibitors | |
| MA37763B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyl and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| MA39253B1 (en) | Substituted bicyclic heteroaryl compounds used as rxr agonists | |
| MA43250B1 (en) | Oxadiazaspiro compounds for the treatment of drug abuse and dependence | |
| MA43158B1 (en) | Oxa-diazadispiro compounds with activity against pain | |
| MA52370B1 (en) | Pyridine derivatives and their therapeutic uses as trpc6 inhibitors | |
| MA39506A1 (en) | Derivatives of 1- (cyclopent-2-en-1-yl) -3- (2-hydroxy-3- (arylsulfonyl) phenyl) urea used as cxcr2 inhibitors |